Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Sporadic Angiomyolipomas (AMLs)
NCT02539459Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Sep 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in angiomyolipoma (AML), sponsored by Fox Chase Cancer Center. Started Sep 2015; status: terminated.
02
Drugs
everolimus
03
Conditions
angiomyolipoma (AML)
Beyond the preview
Go deeper on NCT02539459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539459.